Helus Pharma CEO Departs; Interim Leader Returns Amid Critical Trial Timeline
Event summary
- Michael Cola steps down as CEO of Helus Pharma effective immediately, at the Board's request.
- Eric So, co-founder and Executive Chairman, resumes role as Interim CEO while a permanent successor is sought.
- Helus Pharma's Phase 3 APPROACH trial for HLP003 is expected to deliver topline data in Q4 2026.
- Company focuses on advancing its pipeline of novel serotonergic agonists for mental health conditions.
The big picture
Helus Pharma's leadership transition occurs amid a critical phase in its clinical pipeline, particularly with the Phase 3 trial for HLP003. The company's focus on novel serotonergic agonists positions it within the competitive landscape of mental health treatments, where regulatory recognition and clinical success are key differentiators. The interim leadership change underscores the importance of maintaining momentum in a sector where execution risk is high.
What we're watching
- Leadership Continuity
- How Eric So's return as Interim CEO will impact strategic execution and investor confidence during the transition.
- Trial Momentum
- Whether the upcoming topline data readout from the APPROACH trial will meet regulatory and market expectations.
- Succession Strategy
- The pace at which the Board identifies and appoints a permanent CEO to stabilize leadership.
Related topics